{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T13:00:11Z","timestamp":1780059611814,"version":"3.54.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"DOI":"10.7759\/cureus.106262","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:09:45Z","timestamp":1775041785000},"source":"Crossref","is-referenced-by-count":1,"title":["Profound Synergistic Bradycardia: Pharmacokinetic Consequences of Paxlovid-Mediated CYP3A4 and CYP2D6 Inhibition on Ranolazine, Diltiazem, and Metoprolol"],"prefix":"10.7759","author":[{"given":"Simon B","family":"Bactawar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Gaibor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Abdul-Waheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2020.06.004","article-title":"Novel SARS-CoV-2 outbreak and COVID19 disease; a systemic review on the global pandemic","volume":"7","author":"Al-Rohaimi AH","year":"2020","unstructured":"Al-Rohaimi AH, Al Otaibi F. Novel SARS-CoV-2 outbreak and COVID19 disease; a systemic review on the global pandemic. Genes Dis. 2020, 7:491-501. 10.1016\/j.gendis.2020.06.004","journal-title":"Genes Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7117e1","article-title":"Provisional mortality data - United States, 2021","volume":"71","author":"Ahmad FB","year":"2022","unstructured":"Ahmad FB, Cisewski JA, Anderson RN. Provisional mortality data - United States, 2021. MMWR Morb Mortal Wkly Rep. 2022, 71:597-600. 10.15585\/mmwr.mm7117e1","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2022.128987","article-title":"COVID-19: vaccines and therapeutics","volume":"75","author":"Ponnampalli S","year":"2022","unstructured":"Ponnampalli S, Venkata Suryanarayana Birudukota N, Kamal A. COVID-19: vaccines and therapeutics. Bioorg Med Chem Lett. 2022, 75:128987. 10.1016\/j.bmcl.2022.128987","journal-title":"Bioorg Med Chem Lett"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-023-02134-x","article-title":"OpCitance: citation contexts identified from the PubMed Central open access articles","volume":"10","author":"Hsiao TK","year":"2023","unstructured":"Hsiao TK, Torvik VI. OpCitance: citation contexts identified from the PubMed Central open access articles. Sci Data. 2023, 10:243. 10.1038\/s41597-023-02134-x","journal-title":"Sci Data"},{"key":"ref5","article-title":"Nirmatrelvir-ritonavir","author":"Lam C","year":"2023","unstructured":"Lam C, Patel P. Nirmatrelvir-ritonavir. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00044-022-02951-6","article-title":"The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations","volume":"31","author":"Joyce RP","year":"2022","unstructured":"Joyce RP, Hu VW, Wang J. The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations. Med Chem Res. 2022, 31:1637-46. 10.1007\/s00044-022-02951-6","journal-title":"Med Chem Res"},{"key":"ref7","unstructured":"U.S. Food and Drug Administration. Norvir (ritonavir) capsules, for oral use (prescribing information). (2017). Accessed. March 27, 2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209512lbl.pdf."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/joa3.12578","article-title":"COVID-19 induced bradyarrhythmia and relative bradycardia: an overview","volume":"37","author":"Douedi S","year":"2021","unstructured":"Douedi S, Mararenko A, Alshami A, et al.. COVID-19 induced bradyarrhythmia and relative bradycardia: an overview. J Arrhythm. 2021, 37:888-92. 10.1002\/joa3.12578","journal-title":"J Arrhythm"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.08.800","article-title":"Cardiovascular drug interactions with nirmatrelvir\/ritonavir in patients with COVID-19: JACC review topic of the week","volume":"80","author":"Abraham S","year":"2022","unstructured":"Abraham S, Nooraie RY, Cheng-Lai A, et al.. Cardiovascular drug interactions with nirmatrelvir\/ritonavir in patients with COVID-19: JACC review topic of the week. J Am Coll Cardiol. 2022, 80:1912-24. 10.1016\/j.jacc.2022.08.800","journal-title":"J Am Coll Cardiol"},{"key":"ref10","article-title":"CCBs and CYP3A4 inhibitors: watch out for enhanced cardiovascular response","volume":"27","author":"Horn JR","year":"2016","unstructured":"Horn JR, Hansten PD. CCBs and CYP3A4 inhibitors: watch out for enhanced cardiovascular response. Pharmacy Times. 2016, 27:2026.","journal-title":"Pharmacy Times"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3351","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 genotypes and beta-blocker therapy","volume":"116","author":"Duarte JD","year":"2024","unstructured":"Duarte JD, Thomas CD, Lee CR, et al.. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 genotypes and beta-blocker therapy. Clin Pharmacol Ther. 2024, 116:939-47. 10.1002\/cpt.3351","journal-title":"Clin Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14247","article-title":"CYP2D6 polymorphism and its impact on the clinical response to metoprolol: a systematic review and meta-analysis","volume":"86","author":"Meloche M","year":"2020","unstructured":"Meloche M, Khazaka M, Kassem I, Barhdadi A, Dub\u00e9 MP, de Denus S. CYP2D6 polymorphism and its impact on the clinical response to metoprolol: a systematic review and meta-analysis. Br J Clin Pharmacol. 2020, 86:1015-33. 10.1111\/bcp.14247","journal-title":"Br J Clin Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H423","article-title":"Proposal for a new tool to evaluate drug interaction cases","volume":"41","author":"Horn JR","year":"2007","unstructured":"Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007, 41:674-80. 10.1345\/aph.1H423","journal-title":"Ann Pharmacother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/475016-profound-synergistic-bradycardia-pharmacokinetic-consequences-of-paxlovid-mediated-cyp3a4-and-cyp2d6-inhibition-on-ranolazine-diltiazem-and-metoprolol","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:09:47Z","timestamp":1775041787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/475016-profound-synergistic-bradycardia-pharmacokinetic-consequences-of-paxlovid-mediated-cyp3a4-and-cyp2d6-inhibition-on-ranolazine-diltiazem-and-metoprolol"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.106262","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}